Brought to you by 
Samsung BioLogics raises $1.9bn in IPO
15 Sep 2017
Executive Summary
Samsung BioLogics (Samsung Electronics Co. Ltd.'s drug manufacturing arm) raised $1.9bn in its initial public offering of 16.5mm shares at 136,000 won per share (priced at top of the range) on Korea's KOSPI (Korea Composite Stock Price Index). The IPO values the company at nearly $7.9bn and is the third-largest IPO in South Korea's history.
Deal Industry
- Contract Research Organization-CRO
- Pharmaceuticals
- Services
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Samsung BioLogics raises $1.9bn in IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice